Fig. 5
From: Neuromodulation by nanozymes and ultrasound during Alzheimer’s disease management
A Schematic illustration of the designed RR-11a-loaded and AAN- or RGD-modified nanobubbles for cooperative drug delivery and AEP-targeted AD treatment. NB (11a)-R adhere to endothelial cells and transiently open the BBB upon focused ultrasound oscillations, allowing the rest NBs/localized released RR-11a molecules to enter the brain, and then NB (11a)-A selectively bind with the impaired neurons and deposit therapeutic molecules at the AD lesion. The accumulated RR-11a molecules concurrently inhibit cleavage of Tau and deposition of Aβ in the brain of AD mouse. Reproduced with permission copyright 2022, Elesevier [87]. B Schematic illustration of positive and negative charge enhancement of MoS2 POD catalytic activity for efficient antitumor therapy. Schematic illustration of the synthesis of BTO/MoS2@CA and positive and negative charge promoted dissociation of H2O2. Piezoelectric catalytic therapeutic process of BTO/MoS2@CA under US irradiation. Reproduced with permission copyright 2023, Wiley [88]. C Schematic of the US-switchable enzymatic activity of the Pd@Pt-T790 nanoplatform in different tissues. Reproduced with permission copyright 2020, American Chemical Society [89]. D Schematic Illustration of the Fabrication of the PX@OP@RVG Nanosystem; NPs cross the BBB by receptor-mediated transcytosis and double-targeted treating process In-vitro and In-vivo. Reproduced with permission copyright 2018, American Chemical Society [90]